Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B

VERTEX PHARMACEUTICALS INC / MA

2022-Q3 EPS reported $9.68 revenue$6,628,000,000

Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.
GAAP diluted EPS $3.59; non-GAAP diluted EPS $4.01, up 14% YoY.
Full-year 2022 product revenue guidance raised to $8.8-8.9B from prior $8.6-8.7B.
Initiating global regulatory submissions for exa-cel (sickle cell/beta thalassemia) in 2022; Phase 3 for VX-548 (acute pain) started.
Cash and marketable securities $11.5B as of Sept 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.